www.re-mission.net

The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

My goal is to focus on what I want as a cancer thriver, especially after moving to the other side of the country.

The phase 3 STARGLO study met its primary endpoint of improved overall survival, according to Columvi’s manufacturer, Genetech.